GLPG VS DNLI Stock Comparison

Performance

GLPG
75/100

GLPG returned -9.92% in the last 12 months. Based on SPY's performance of -13.22%, its performance is above average giving it a score of 74 of 100.

DNLI
10/100

DNLI returned -38.93% in the last 12 months. Based on SPY's performance of -13.95%, its performance is below average giving it a score of 10 of 100.

Analyst Price Targets

GLPG
78/100

8 analysts offer 12-month price targets for GLPG. Together, they have an average target of 88.89, the most optimistic target put GLPG at 97 within 12-months and the most pessimistic has GLPG at 83.74.

DNLI
69/100

4 analysts offer 12-month price targets for DNLI. Together, they have an average target of 91, the most optimistic target put DNLI at 112 within 12-months and the most pessimistic has DNLI at 70.

Technicals

GLPG
71/100

GLPG receives a 71 of 100 based on 14 indicators. 9 are bullish, 3 are bearish.

DNLI
21/100

DNLI receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

Earnings

GLPG
10/100

GLPG has missed earnings 10 times in the last 20 quarters.

DNLI
10/100

DNLI has missed earnings 10 times in the last 20 quarters.

Profit

GLPG
40/100

Out of the last 20 quarters, GLPG has had 8 profitable quarters and has increased their profits year over year on 6 of them.

DNLI
13/100

Out of the last 20 quarters, DNLI has had 3 profitable quarters and has increased their profits year over year on 2 of them.

Volatility

GLPG
50/100

GLPG has had an average amount of volatility over the last 12 months giving it a score of 50 of 100.

DNLI
46/100

DNLI has had a lower than average amount of volatility over the last 12 months giving it a score of 46 of 100.

All score calculations are broken down here to help you make more informed investing decisions

Galapagos NV Summary

Nasdaq / GLPG

Healthcare

Biotechnology

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Denali Therapeutics Inc. Common Stock Summary

Nasdaq / DNLI

Healthcare

Biotechnology

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Power up your portfolio